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Abstract: The blood-brain barrier (BBB) is a highly specialized structural and biochemical barrier that regulates the entry 
of blood-borne molecules into brain, and preserves ionic homeostasis within the brain microenvironment. BBB properties 
are primarily determined by junctional complexes between the cerebral endothelial cells. These complexes are comprised 
of tight and adherens junctions. Such restrictive angioarchitecture at the BBB reduces paracellular diffusion, while mini-
mal vesicle transport activity in brain endothelial cells limits transcellular transport. Under normal conditions, this largely 
prevents the extravasation of large and small solutes (unless specific transporters are present) and prevents migration of 
any type of blood-borne cell. However, this is changed in many pathological conditions. There, BBB disruption (“open-
ing”) can lead to increased paracellular permeability, allowing entry of leukocytes into brain tissue, but also contributing 
to edema formation. In parallel, there are changes in the endothelial pinocytotic vesicular system resulting in the uptake 
and transfer of fluid and macromolecules into brain parenchyma. This review highlights the route and possible factors in-
volved in BBB disruption in a variety of neuropathological disorders (e.g. CNS inflammation, Alzheimer’s disease, Park-
inson’s disease, epilepsy). It also summarizes proposed signal transduction pathways that may be involved in BBB “open-
ing”. 
INTRODUCTION 
  “Good fences make good neighbors.” The blood-brain 
barrier (BBB) is a highly specialized structural, transport and 
biochemical (enzymatic) barrier, that mainly consists of mi-
crovascular endothelial cells and overlying astrocytic foot 
processes. It regulates the entry of compounds and cells be-
tween blood and brain and, thus, has a fundamental role in 
brain homeostasis. It also, though, forms a route of commu-
nication between circulating blood and underlying brain tis-
sues [125,142,173]. Much of the structural barrier is due to 
the presence of tight junctions between the cerebral endothe-
lial cells that limit paracellular diffusion. Those junctions, 
how they are regulated, how they are affected by disease 
states and how they can be manipulated therapeutically is the 
main focus of this review. Other reviews discuss other BBB 
properties (e.g. transport and enzymatic barrier properties) in 
depth. 
BBB STRUCTURE: THE JUNCTIONAL COMPLEXES 
  BBB properties are primarily determined by endothelial 
junctional complexes consisting of tight junctions (TJ) and 
adherens junctions (AJ). It is generally accepted that TJ seal 
the interendothelial cleft forming a continuous blood vessel, 
while the AJ are important for initiating and maintaining 
endothelial cell-cell contact [60,142]. The tight junctions 
between BBB endothelial cells lead to high endothelial elec-
trical resistance and low paracellular permeability. The elec-
trical resistance is in the range of 1500-2000 .cm
2 (pial 
vessels) compared to 3-33 .cm
2 in other tissues [27,40].  
  TJ and AJ are composed of transmembrane proteins and 
cytoplasmic plaque proteins (Fig. 1, Table 1). The former   
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proteins physically associate with their counterparts on the 
plasma membrane of adjacent cells, whereas the latter pro-
vide a link between transmembrane TJ/AJ proteins and the 
actin cytoskeleton but also participate in intracellular signal-
ing [60,142].  
  Transmembrane proteins of the TJ include occludin, 
claudins (for example, claudin-3, -5, -12) and junctional ad-
hesion molecule (JAM)-A, JAM-B and JAM-C [32,60,103]. 
Occludin was one of the first TJ transmembrane proteins 
described. Structurally, occludin contains two equal extracel-
lular loops (44 amino acids), four transmembrane domains 
and three cytoplasmic domains: one intracellular short turn, a 
small N-terminal domain and a long carboxyl (C-) terminal 
[60,92,119,150]. It is thought that both of the extracellular 
loops provide the gate and fence-like structure of TJs, al-
though the function of first extracellular loop is mostly in-
volved in intercellular adhesion, while second loop mostly 
affects transendothelial electrical resistance [50,119]. The C-
terminal domain (150 amino acids) of occludin is remarkably 
conserved between species and it is predicted to form a typi-
cal  -helical coiled-coil structure [92,119]. Through this 
structure occludin can associate with ZO-1, ZO-2 and ZO-3, 
directly bind to F-actin, and interact with regulatory protein 
PKC, tyrosine kinase c-Yes, PI3K and gap junction compo-
nent connexin 26 [4,35,85,129,165,168]. As well as being 
involved in the integration and function of occludin in the TJ 
complex, this part of the molecule plays a critical role in 
paracellular channel formation and in mediating the endocy-
tosis and trafficking of occludin [73,112,168]. The N-
terminal site is critical for occludin function as an adhesion 
molecule and a N-terminal occludin mutant may be unable to 
fully oligomerize and completely assemble in TJ complexes 
[148].  
  Claudins are principal barrier-forming proteins that be-
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[for review see 14, 36, 60, 70]. Until now, twenty different 
claudins have been identified and each of them shows a 
unique pattern of tissue expression. All claudins have the 
same structural pattern: four membrane-spanning regions, 
two extracellular loops and two cytoplasmic termini: a very 
short internal N-terminal sequence (2-6 amino acids) and a 
longer internal C-terminal sequence (21-63 amino acids) 
[36,70]. The first extracellular loop (49-52 amino acids) in-
fluences paracellular charge selectivity, while the second 
extracellular loop (16-33 amino acids) is the receptor for a 
bacterial toxin [56,60,80,143]. The C-terminus possesses the 
binding site for the cytoplasmic proteins ZO-1, ZO-2, ZO-3, 
MUPP1, PATJ through a PDZ motif [56,64,143]. Claudins 
function in the TJ complex is to limit paracellular ion 
movement selectively and this produces the high electrical 
resistance of the barrier [104,178]. Brain endothelial cells 
possess the claudin-5 and claudin-12 and possibly some 
other claudins [112,160]. Claudins present in brain endothe-
lial cells may form pores of variable size (~10Å) which may 
be involved in transjunctional movement of water [17,104, 
121,178]. Claudin-5 deletion did not inhibit tight junction 
formation but did result in a size-selective increase in perme-
ability [70,110]. 
  JAMs (JAM-A, -B, -C) are members of the immuno-
globulin superfamily [15,16]. These molecules structurally 
are composed of a single membrane spanning domain, an 
extracellular domain, an extracellular N-terminus, and a 
short cytoplasmic C-terminus [15,16,159,186]. The extracel-
lular region of JAMs consists of two IgG-like domains. 
These are often subclassified as C1-,  C2-, V- and I-type 
based on the variable and constant regions of antibodies 
[15,159,186]. The extracellular domain appears to be subject 
of glycosylation, although the function of this is still un-
known [186]. The N-terminal loop can be dimerized. The 
short C-terminus cytoplasmic tail (40 amino acids) contains 
a PDZ binding domain which facilitates interactions with TJ 
associated scaffold proteins such as ZO-1, AF-6, ASIP/Par3, 
and cingulin [74,124]. The cytoplasmic tail also contains 
consensus phosphorylation sites that may serve as substrates 
for PKC and PKA [36,123,165]. New evidence also suggests 
that this cytoplasmic tail may be involved in targeting JAM 
to intercellular junctions. In general, JAMs are expressed at 
the intracellular junctions of endothelial and epithelial cells 
and display different patterns of homo- and heterophilic ad-
hesion [15,86,144]. Homophilic interactions are with mole-
cules on the opposite cell, forming JAM dimers that are part 
of tight junction structure [15,144]. Heterophilic interactions, 
however, can occur between different JAM family members 
as well as other adhesion molecules (e.g. integrins) and their 
function is still unknown [86]. Regarding the function JAMs 
at the level of the TJ complex, these molecules are involved 
in promoting the localization of ZO-1, AF6, CASK and oc-
cludin at points of cell contact and, via targeting Par3, are 
involved in establishment of cell polarity [16,74]. There is 
also convincing evidence supporting a role for the members 
of JAM family in the migration of leukocytes across endo-
thelial junctions [7,16,53].  
  The TJ cytoplasmic plaque proteins are subdivided de-
pending on whether they contain a PDZ motif. PDZ contain-
ing proteins include members of the family membrane-
associated guanylate-kinase (MAGUK) homologues (ZO-1, -
2, -3), partitioning-defective proteins (Par)3, Par6, afidin/Af-
6, etc [60,61,132]. These proteins contain a PDZ motif (80-
90 amino acids) on the carboxyl terminal that can mediate 
interactions with other proteins, transmembrane proteins or 
with PDZ motifs on other proteins [60,61,152]. The PDZ 
domain is critical for clustering and anchoring of transmem-
brane proteins. Most of these proteins contain multiple PDZ 
domains, so they may act as scaffolds that bring together 
cytoskeleton, signaling and integral proteins at specific 
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Table 1.  Proteins Identified in Brain Endothelial Junctional Complex 
Junctional Com-
plex 
Proteins 
(Molecular Weight) 
Localization Function  Ref. 
Occluding 
(~65 kDa) 
membrane; multi-pass membrane 
protein; cell-cell contact, tight 
junction 
formation and regulation of TJ paracellu-
lar barrier permeability; interacts with ZO-
1, ZO-2, ZO-3, F-actin  
[50,60,119] 
claudin 3, -5, -12 
(~20-27 kDa) 
membrane; multi-pass membrane 
protein; cell-cell contact, tight 
junction 
tight junction-specific obliteration of the 
intercellular space; directly interacts with 
ZO-1, ZO-2 and ZO-3. 
[60,70,111,178] 
JAM-A, -B and –C 
(32-40 kD) 
membrane; single-pass type I 
membrane protein; cell contact, 
tight junction 
JAM-A (tight junction formation, neutro-
phile and monocytes transmigration; inter-
action with Par3); JAM-B lymphocytes 
transmigration; interaction with JAM-C); 
JAM-C (cell-cell adhesion, leukocytes 
transmigration; interaction with JAM-B) 
[15,186,74,144] 
ZO-1, ZO-2, ZO3 
(210-225kD, 160 kD, 130 kD) 
cytoplasm; the cytoplasmic face 
of tight and adherens junction 
ZO-1 (stabilization of junctions, signal 
transduction; interact with occludin, 
claudins, cingulin, ZO-3); ZO-2 (stabili-
zation of TJ and AJ, interacts with oc-
cludin); ZO-3 (interacts with occludin, 
claudins and ZO-1) 
[49,61,132,175] 
Par-3, Par-6 
(100-180kDa, ~37kDa) 
cytoplasm; intracytoplasmic 
membrane; the cytoplasmic face 
of tight junctions 
Tj assembly, the Par6-Par3 complex links 
GTP-bound Rho small GTPases to atypi-
cal protein kinase C proteins 
[61,132] 
Afidin/AF-6 
(~205kD) 
cytoplasm; the cytoplasmic face 
of tight junctions 
assembly of TJ and AJ; interaction JAMs, 
cadherins catenins, F-actin, nectin 
[61,132] 
Cingulin 
(108kD and 140 kD) 
cytoplasm; the cytoplasmic face 
of tight junction 
formation and regulation of the TJ perme-
ability, anchoring the Tj proteins to actin-
based cytoskeletons; interaction with ZO-1 
and JAMs 
[32,39] 
7H6 
(~155kD) 
cytoplasm; colocalizes with actin 
stress fibers 
F-actin cross-linking protein, anchor actin 
to other Tj and AJ proteins; interact with 
ZO-1, -catenin 
[146] 
Rab3b, Rab13 
(~25kD, ~23kD) 
lipid-anchor; the cytoplasmic 
face of tight junctions; cytoplas-
mic vesicle membrane 
participation in polarized transport, as-
sembly and/or activity of tight junctions 
[112,169] 
PKC, PKC 
(68-80kD, ~74kD) 
cytoplasm, membrane, en-
dosome 
cell polarization processes, biogenesis of 
TJ; interaction with Par3, Par6, Rac, 
Cdc42, actin cytoskeleton 
[165,187] 
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G protein 
Gi, Gs, G12, Go 
membrane; multi-pass membrane 
protein; cell-cell contact, tight 
junction 
Tj biogenesis, stabilization of TJ, regula-
tion of permeability 
[108] 
Ve-cadherin 
(~130kD) 
 membrane; single-pass type I 
membrane protein, cell-cell and 
cell-matrix boundaries. 
control the cohesion and organization of 
the intercellular junctions;  
[114,142] 
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catenin , ,  (plakoglobin), 
p120 
(100kD, 94kD,81 kD,120kD) 
multiprotein cell-cell adhesion 
complex; cytoplasm; the cyto-
plasmic side of adherens junc-
tion; cytoskeleton, 
with Ve-cadherin produces a complex 
which is linked to the actin filament net-
work, and it is important for Ve-cadherin 
cell-adhesion properties 
[69,114] 
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regions of the plasma membrane [107,175]. For example, 
ZO-1 is thought to function as a multidomain scaffold that 
coordinates assembly of transmembrane and cytosolic pro-
teins into TJ and/or regulates the activity of these proteins 
once they are assembled. ZO-1 binds to all three classes of 
TJ transmembrane proteins including occludin, claudins and 
CTX (IgG superfamily), but it also binds to 10 cytoplasmic 
proteins and various components of the cortical cytoskeleton 
[49,152,175]. In this case, ZO-1 is required for the normal 
kinetics of TJ assembly, for TJ specific localization and 
unique organization of transmembrane proteins [32,61].  
  PDZ lacking plaque proteins include as cingulin, 7H6, 
Rab13, ZONAB, AP-1, PKC, PKC, heterotrimeric G pro-
tein. These proteins exert a variety of functions at the TJ 
complex. Cingulin, for example, act as a cross link between 
TJ proteins (ZO-2, ZO-3, AF-6, JAM) and the actin-myosin 
cytoskeleton [32,39]. 7H6 mostly plays a role in TJ mainte-
nance and maturation, while ZONAB is a transcription factor 
that regulates ErbB transcription and paracellular permeabil-
ity [8,146]. Rab proteins (Rab13, Rab3b) have a role in 
docking and fusion of transport vesicles at the TJ complex 
[169]. PKC and PKC are involved in regulation of polari-
zation as well as in TJ assembly, while G proteins (G-i0, G-
i2, G12, Gs) co-immunoprecipitate with ZO-1 and play a 
role in accelerating TJ assembly and maintaining transendo-
thelial electrical resistance [55,108,165,187]. 
  Vascular endothelium cadherin (Ve-cadherin) is the ma-
jor transmembrane protein of the endothelial AJ. A member 
of the large family of cadherins, it interacts homotypically in 
the presence of Ca
2+. The AJ cytoplasmic plaque includes 
proteins of the catenin family (, , , p120) [15,114]. Ve-
cadherin is an important determinant of microvascular integ-
rity both in vitro and in vivo and together with catenin forms 
a complex that function as an early recognition mechanism 
between endothelial cells. [15,114,142,173]. It is believed 
that - and -catenin link the cadherin to -catenin which, in 
turn, couples the complex to the actin microfilament network 
of the cell skeleton [15,114,142,173]. A new p120 catenin 
was recently identified [15]. Its role remains controversial in 
contrast to the above-mentioned classical catenins but high 
affinity binding of p120 catenin to Ve-cadherin suggest that 
it may regulate vascular permeability and affect BBB func-
tion [15, 69, 114].  
BBB STRUCTURE: THE CYTOSKELETON 
  The brain endothelial cytoskeleton has a critical role in 
establishing interendothelial junctional integrity. The cy-
toskeleton is composed of three primary elements: actin mi-
crofilaments, intermediate filaments and microtubules [68, 
85,156,182]. The actin microfilament system is focally 
linked to multiple membrane adhesion proteins including 
cadherin or occludin, glycocalix components, functional in-
tercellular proteins like zona occludens (ZO), catenins and 
focal adhesion complexes [85,167,182]. Short radial bands 
of F-actin: TJ and AJ actin-associated proteins are assembled 
to form a structure denoted as the actin-rich adhesion belt 
[68,156,182]. Actin structure is intimately involved in endo-
thelial cells tension force generated via myosin light chain 
phosphorylation and actin stress fiber formation [78,151].  
  A second major element of the cytoskeletal structure of 
the brain endothelial cell is the microtubule system. Poly-
mers of - and -tubulin form a lattice network of rigid hol-
low rods that span the cells in a polarized fashion from the 
nucleus to the periphery. Microtubules participate in rapid 
assembly of actin filaments and focal adhesion, isometric 
cellular contraction and/or increased transendothelial leuko-
cyte migration. Some recent studies suggest that these func-
tions are realized via interactions of microtubules with mi-
crofilaments [71,172].  
  Intermediate filaments, of which vimentin in the major 
protein in endothelial cells, are the third element involved in 
the cytoskeletal structure. The possible role of these fila-
ments in cytoskeletal changes is still unclear although some 
recent studies indicate dynamic changes in vimentin during 
the reorganization of actin filaments and microtubules [85].  
BBB FUNCTION: VESICULAR SYSTEM, ENZY-
MATIC BARRIER AND TRANSPORT  
  Before discussing how BBB junctions are regulated and 
affected by disease, it is necessary to put those junctions into 
the context of other BBB properties. These include the gen-
eral paucity of vesicular transport at the BBB, the presence 
of enzymes that by degradation prevent the entry of a variety 
of compounds, and the presence of a wide range of transport 
systems. Because non-lipid soluble compounds only diffuse 
slowly across the BBB, the latter are necessary for both the 
entrance of nutrients into brain and the clearance of waste 
products from brain. 
  The cytoplasm of brain endothelial cell is of uniform 
thickness, with very few pinocytotic vesicles and a lack of 
fenestrations. The wall thickness of brain capillaries is ap-
proximately 40% of that in other types of endothelial cell 
[37].  It is speculated that this decrease in wall thickness 
could be an adapation to the restrictive permeability of the 
BBB, allowing nutrients a shortened transport time to cross 
through the membrane and cytoplasm, and enter the brain 
parenchyma [37]. 
  In general, brain endothelial cells have a very low num-
ber of vesicles under normal conditions compared to other 
types of endothelial cells. However, during some disease 
states (e.g. inflammatory conditions) the number of vesicles 
can increase. The classic type of caveole (-shaped cell sur-
face invagination, open or close) is one of the most predomi-
nant forms of vesicles [34, 97, 98, 154, 166]. Fusion between 
vesicles may eventually lead to the formation of transendo-
thelial channels and/or vesicle/vacuolar organelles (VVO). 
Transendothelial channels correspond to chains of two or 
more fused vesicles that are open simultaneously on the lu-
minal and abluminal side of endothelial cells [34,97,154, 
166]. Besides that, channels made by one of the vesicle open 
on the both sides of endothelial cells can occur. VVO on the 
other hand are large collection of interconnected vesicles and 
vacuoles [98,166]. Fusion of vesicles, vacuole with luminal 
and abluminal plasma membranes create transcellular path-
ways confirmed in the several ultrastructural studies 
[29,37,98]. Brain endothelial cells also possess a well devel-
oped tubular system formed by membrane-bound tubules 
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luminal and abluminal poles. The tubular system also opens 
at the level of the lateral intercellular space and branches off 
in different directions forming an intracellular network re-
sembling a tree-like structure. This network is involved in 
the transport of circulating proteins and could be involved in 
transendothelial leukocyte migration [29,37,97]. 
  The BBB is an enzymatic barrier, capable of metaboliz-
ing drug and nutrients [25,104]. These enzymes are princi-
pally directed at metabolizing neuroactive blood-borne sol-
utes. Enzymes such as -glutamyl transpeptidase (-GTP), 
alkaline phosphatase, and aromatic acid decarboxylase are 
found at elevated concentrations in cerebral microvessels, 
yet are often in low concentration or absent in non-neuronal 
capillaries. These enzymes are often polarized between the 
luminal and abluminal membrane surface of brain endothe-
lial cells. This concept is supported from several quantitative 
biochemical studies [18]. The enzymes -GTP and alkaline 
phosphatases are presented at the luminal endothelium [19]. 
  The BBB possesses a wide array of transporters. Because 
of the occluded paracellular pathway, nutrients must cross 
the endothelial cell to gain access to brain from blood. Thus, 
for example, the BBB has very high levels of the glucose 
transporter GLUT1, and the large neutral amino acid trans-
porter, LAT1, that facilitate movement of those nutrients 
from blood to brain [20,21]. There are also efflux transport-
ers that move compounds from brain to blood. These trans-
porters, such as P-glycoprotein and organic anion transport-
ers, are involved in clearing waste products from the brain or 
preventing the entry of potentially neurotoxic compounds 
from blood to brain [41,94]. Other transporters are involved 
in ion homeostasis and the transport of signaling molecules 
between blood and brain. Many of these transporters have a 
polarized distribution at the cerebral endothelium. For exam-
ple, Na
+-K
+-ATPase and the sodium-dependent neutral amino 
acid transporter (A-system) are associated with the abluminal 
portion of the endothelium [19]. Such structural, pharmacol-
ogical and biochemical evidence for luminal and abluminal 
polarization of receptors, enzymes, and channels at the cere-
bral endothelium established the BBB to be a working, non-
stagnant, membrane unequivocally evolved to maintain brain 
homeostasis.  
  Besides transporters, brain endothelial cells posses sev-
eral ion channels, which control important endothelial func-
tions. Ion channels are involved in the production and release 
of vasoactive factors (nitric oxide and prostacyclin), traffick-
ing and secretion of haemostatic factors (von Willebrand, 
tissue type plasminogen activator) and enhancing flux of 
Ca
2+ [46,81]. 
  Ions or small molecules like amino acids and glucose are 
mostly transferred through the brain endothelial cells by 
transporters/carriers/channels present on the plasma mem-
brane. Most macromolecules move across brain capillary 
endothelium by bulk phase non-receptor mediated endocyto-
sis. For example, cationic macromolecules prefer uptake by 
clathrin coated membranes and pits and are subsequently 
delivered to and degraded in lysosomes [97]. In contrast, 
anionic molecules, which include most plasma proteins, un-
dergo fluid internalization by apical caveolae and are shut-
tled to the basal side [97,115]. In general, pathological in-
creases in BBB permeability are mostly associated with in-
creased paracellular permeability although changes in tran-
scellular flux may contribute.  
PHYSIOLOGY OF THE BBB: TRANSPORT 
THROUGH THE BBB (PARACELLULAR AND 
TRANSCELLULAR) 
  These trans- and paracellular pathways differ with re-
spect to physical properties: a) the transport across the tran-
scellular pathway can be either passive or active while pas-
sage trough paracellular route is exclusive passive and it is 
driven by electrochemical, hydrostatic and osmotic gradi-
ents, b) compared to the transcellular route, the paracellular 
pathway is characterized by higher conductance and lower 
selectivity; c) paracellular transport is not rectified with the 
similar conductance and selectivity in either apical to basal 
or basal to apical directions; d) paracelluar pathways have 
well defined values of electrical conductance as well as 
charge and size selectivity [14].  
  The paracellular permeability of the BBB is maintained 
by equilibrium between the contractile force generated at the 
endothelial cytoskeleton and adhesive forces produced at 
endothelial cell-cell junctions and cell-matrix contacts [58, 
176]. A dynamic interaction among these structural elements 
controls the opening and closing the paracellular pathway 
and thus serves as a fundamental mechanism in regulation of 
the blood-brain exchange [58]. The unperturbed endothelial 
barrier has restrictive properties that are due primarily to the 
closed junctional complex. Factors which increase paracellu-
lar permeability act on the junctional complex resulting in 
the formation of minute intercellular gaps which can allow 
the passage of plasma proteins (e.g. albumin), fluid and leu-
kocytes across the barrier. The processes by which interen-
dothelial gaps are formed are the subject of intense investiga-
tion. There are two ongoing and probably simultaneous 
processes: changes in adhesive properties of TJ and AJ pro-
teins and reorganization of the actin cytoskeleton.  
  The changes in adhesive property of TJ and AJ proteins 
are mostly correlated with alterations in their phosphoryla-
tion state. In general, the TJ proteins (e.g. occludin,
 ZO-1, 
ZO-2, and claudin-5) are phosphoproteins and changes in 
phosphorylation state affect their interaction, alter trans-
membrane protein localization and induce their redistribution 
[65,77,95,160,162]. Phosphorylation of TJ proteins can oc-
cur on amino acid residues Ser-, Thr-, and Tyr- although the 
exact position/sites of phosphorylation in the brain endothe-
lial cells is still unknown. Analyzing published studies about 
the phosphorylation pattern of TJ and AJ protein in brain 
endothelial cells, it appears that type of phosphorylation 
mostly depends on the type of stimulii as well as the local 
microenvironment. For example, vascular endothelial
 growth 
factor and CCL2 induce Ser/Thr phosphorylation and redis-
tribution
 of occludin and ZO-1 in murine brain endothelial 
cells, and oxygen mediators induce primarily Tyr-phospho-
rylation and reorganization of the TJ complex [65,67,77, 
162]. However, in conditions like calcium depletion, phorbol 
ester treatment
 or bacterial infection, TJ proteins (occludin) 
undergo dephosphorylation
 during TJ disruption rather than 
additional phoshorylation [33,91,113]. Similar to TJ pro-
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phosphorylation of Ser/Thr and Tyr residues during opening 
of brain endothelial barrier [82,134,188].  
  Phosphorylated TJ and AJ proteins undergo redistribu-
tion, a critical event for the changes of adhesive contact be-
tween brain endothelial cells. A complete redistribution of TJ 
proteins can be seen at the time of lowest transendothelial 
electrical resistance and highest permeability coefficients for 
the tracers such as FITC-albumin, inulin and mannitol 
[162,163]. However there is still not firm evidence on how 
redistribution occurs. Simultaneous, and closely associated 
with junction protein modification, there is actin cytoskele-
ton reorganization [16,163]. Actin filament polymerization, 
actin myosin association and generation of intraendothelial 
contractile forces, results in “pulling in” of the contact sur-
face between brain endothelial cells which may also result in 
the dislocation of transmembrane tight and adherence junc-
tion proteins [158]. 
FACTORS INVOLVED IN PARACELLULAR AND 
TRANSCELLULAR BRAIN ENDOTHELIAL BAR-
RIER “OPENING” 
  Depending on the individual pathology, a variety of the 
factors are involved in altering BBB permeability. Several 
groups of mediators appear to have a prominent role in BBB 
disruption. These include a group of vasogenic agents in-
cluding histamine, substance P, endothelin-1 and bradikinin; 
growth factors such as vascular endothelial growth factor 
(VEGF), basic fibroblast growth factor bFGF and transform-
ing growth factor– (TGF); a heterogenic group of inflam-
matory mediators including cytokines [interleukin-1 (IL-
1), tumor necrosis factors- (TNF-), interferon- (INF- )] 
and chemokines (CCL2 and CXCL8); matrix metalloprote-
inases (MMP2 and MMP9); free radicals such as O2
-, H2O2, 
OH
- NOO
- and lipid mediators including prostaglandin E2 
and F2a [1,6,43,45,99,115,127,136,137,164,190]. Potent 
inducers of BBB hyperpermeability are also thrombin, amy-
loid-, intracellular Ca
2+ and blood-borne cells like leuko-
cytes where direct interaction with brain endothelial cells 
causes BBB “opening” [2,23,88,100].  
  Infective agents may also cause BBB disruption. The 
interactions of these agents with brain endothelial cells is 
crucial in the pathogenesis of meningitis, and encephalitis 
particularly in BBB “opening” and their passage into brain 
parenchyma. Bacteria and bacterial toxin (Escherichia coli, 
Citrobacter freundii,  Streptococcus pneumoniae and ly-
popolysaccarides,  Cholera toxin, pertussin toxin, respec-
tively), viruses and virus components (HIV-1, Measles virus-
NP), parasites and fungal pathogens not only penetrate 
through the BBB, they also contribute to its breakdown 
[79,123,131,171]. Microorganisms appear to be adapted and 
breached the barrier either by targeting junctions or cells. 
Chlamydia pneumonia exposure to brain capillary endothelia 
decreases occludin expression while increasing expression of 
cell-adhesion proteins [101]. The fungal pathogen Crypto-
coccus neoformans, which causes meningitis, alters subcellu-
lar occludin localization in human brain capillaries [31]. 
  Despite intense investigation, there are still numerous 
controversies over how most of these factors affect the BBB. 
Some of the factors appear to exclusively affect the paracel-
lular permeability (e.g. IL-1 and CXCL8), while some oth-
ers predominantly act to increase transcellular permeability 
(e.g. TNF-) [1]. In addition, the duration of BBB disruption 
may differ between mediators. Some mediators, e.g. hista-
mine, cause a rapid and transient opening of the BBB related 
to a fast cytoplasmic accumulation of Ca
2+, while others, e.g. 
thrombin, cause prolonged opening of BBB related to robust 
changes in the endothelial cytoskeleton [176]. 
SIGNAL TRANSDUCTION PATHWAYS REGULAT-
ING PARACELLULAR AND TRANSCELLULAR 
PERMEABILITY 
  The regulation of paracellular permeability involves 
complex interactions between several agonist-activated sig-
naling pathways and key structural components of the endo-
thelial cells. The latter include, but are not limited to, TJ pro-
teins. One of the most extensively studied regulators of TJ 
and TJ-mediated permeability is protein kinase C (PKC). TJ 
proteins are phosphoproteins which possess several phos-
phorylation sites which could be affected during the brain 
endothelial TJ complex disassembly. PKCs are a family
 of 
serine/threonine kinases that regulate a variety of cell
 func-
tions including proliferation, gene expression, cell cycle,
 
differentiation, cytoskeletal organization, cell migration and
 
apoptosis [133]. The PKC family includes
 isozymes (PKC-, 
ßI, ßII, , ,   ,  	 ,  μ ,  
  ,   ,   ,   ,) which are involved in 
signal transduction from membrane
 receptors to the nucleus 
[122,133]. Some of the PKC isoforms are denoted as critical 
molecules in phosphorylation of TJ proteins. For example, 
activation of three PKC isoforms (PKC-/II, PKC (pan)-II 
and PKC-/) by viral gp120 leads to cytoskeleton altera-
tions and increased monocyte migration [67,79,162]. Under 
hypoxic and post-hypoxic reoxygenation conditions and un-
der the influence of endothelin-1, PKC-II, PKC-, PKC- 	, 
PKC- and PKC regulate TJ disassembly [51,83,126]. Or 
CCL2 activation PKC isoforms PKC and PKC induced 
phosphorylation of TJ proteins (occludin, claudin-5, ZO-1 
and ZO-2) and brain endothelial barrier hyperpermeability 
[162]. However, it is very important to note that the activa-
tion of PKC isoforms is dependent on the type of activator as 
well as the type of the endothelial cells. Some PKC isoforms 
can have opposite roles in different types of endothelial cell. 
For example, in retinal endothelial cells, VEGF via PKCII 
induces phosphorylation of occludin and increases perme-
ability, but in brain endothelial cells this PKC isoform plays 
a protective role in VEGF-induced hyperpermeability [67, 
161]. Therefore, it is critical to precisely define when and 
which type of PKC isoform is activated in brain endothelial 
cells under different conditions. 
  Besides serine/threonine residues, phosphorylation of 
tyrosine residues on TJ and AJ proteins also has a significant 
role in brain endothelial barrier disassembly. Protein tyrosine 
kinases (PTKs) are enzymes which catalyze the phosphoryla-
tion of tyrosine residues. There are two main classes of 
PTKs: receptor PTKs and cellular, or non-receptor, PTKs 
[120]. In regulation of brain endothelial barrier permeability, 
both classes of PTK play an important role. Receptor PTKs, 
which have extracellular domains with one or more identifi-
able structural motifs, have binding sites for several growth 
factors including EGFR, Eph, FGF, PDGF or VEGF, which Brain Endothelial Cell-Cell Junctions  Current Neuropharmacology, 2008, Vol. 6, No. 3    185 
are involved in BBB hyperpermeability [12,28,120]. For 
example, VEGF via receptor Flt-1 and its downstream sig-
naling molecules like phosphatidylinositol 3-kinase/Akt 
(PI3-K/Akt), nitric oxide syntheses (NOS) and protein kinase 
G (PKG) can cause brain endothelial hyperpermeability and 
brain edema formation [41,181]. On the other hand, VEGF 
action via flk-1/KDR could induce specific Tyr-phosphory-
lation of the endothelial adherens junction components VE-
cadherin,  -catenin, plakoglobin, and p120 [150]. Similar 
effects occur with vascular permeable factor (VPF) which 
via Flk-1 (VEGF-R2) and activation of membrane-associated
 
kinases, such as Src and PI3K,
 induces increased BBB per-
meability and the development of local edema [150]. It is 
important to note that activation of PTK can also trigger ac-
tivation and interaction with some other signaling molecules 
like nitric oxide (NO), ERK1/2, and PKC in relation to vas-
cular permeability regulation.
  
  In contrast to receptor PTKs, cellular PTKs are located in 
the cytoplasm, nucleus or anchored to the inner leaflet of the 
plasma membrane. They are grouped into eight families: Src, 
JAK, ABL, FAK, FPS, CSK, SYK and BTK [12,28,120]. 
Each family consists of several members. With the exception 
of homologous kinase domains (Src Homology 1, or SH1 
domains), and some protein-protein interaction domains 
(SH2 and SH3 domains), they have little structural similarity 
[120]. The cellular PTKs are involved in cell growth, cell 
differentiation, and/or cell adhesion. Some members of this 
family (e.g. JAKs), have a role in phosphorylation of STAT 
transcription factors [54,120]. Reactive oxygen species are 
thought to primarily act through these kinases. For instance, 
reactive oxygen species generated during ischemia, brain 
injury, monocytes/neutrophil activation or alcohol exposure 
can activate matrix metalloproteinases (MMP-1, -2, and -9) 
and decrease tissue inhibitors of MMPs (TIMP-1 and -2) in a 
PTK-dependent manner [65,66]. The increase in MMPs and 
PTK activation is associated with degradation of endothelial 
basement membrane and enhanced tyrosine phosphorylation 
of TJ protein. Such changes may result in increased perme-
ability and monocyte migration in stroke, in HIV-1 encepha-
litis, or in multiple sclerosis [20,140,170]. Pretreatment with 
PP1 could improve outcomes in the most of these conditions 
and strongly suggests a possible role of Src tyrosine kinase 
in BBB permeability regulation [65,66].  
  Mediators of oxidative stress also regulate brain endothe-
lial permeability via a complex system of MAP kinases (p38, 
ERK1/2). MAP kinase could be a “nodal point” in, for ex-
ample, PTK signaling [52]. However, it may also be a direct 
executor of TJ protein phosphorylation in conditions like 
exposure to 4-hydroxy-2-nonenal (4-HNE), one of the major 
biologically active aldehydes formed during inflammation 
and oxidative stress [174]. Human immunodeficiency virus-1 
(HIV-1) Tat protein exerts similar effects, regulating expres-
sion of claudin-5 mRNA in brain endothelial cells via 
ERK1/2 activation but simultaneous activation of ERK1/2, 
PI-3K, and nuclear factor-B (NF-B) mediated alterations 
and distribution of claudin-5 protein levels in Tat treated 
brain endothelial cells [3]. Chronic exposure to alcohol with 
simultaneous treatment with lipopolysaccharide (an inflam-
matory mediator) also triggers brain endothelial barrier 
“opening” and TJ protein phosphorylation via activation of 
ERK 1/2 and p38 kinase as well as Jun-N-terminal Kinase 
(JNK) and activation of NFB RelA-p50 [155].  
  In recent years, significant attention has focused on the 
family of small RhoGTPases as major regulators of TJ for-
mation, maintenance and disruption. Rho, GEF-H1 a guanine 
nucleotide exchange factor for Rho, Rac, CdC42 and ROCK 
are some of the member of RhoGTPase family [75]. They 
are known to mediate cytoskeletal contractile responses via 
myosin ATPase activity. For example, ROCK promotes 
phosphorylation of the regulatory light-chain of myosin 
(MLC) on Ser19 and Thr18 through phosphorylation of the 
myosin light-chain phosphatase (MLCP) and via blocking of 
MLC dephosphorylation. This site-specific phosphorylation 
of MLC in turn elevates myosin ATPase activity, leading to 
actin-myosin contraction [116,118]. This pathway has been 
described as a mechanism underlying “long-lasting” altera-
tions in endothelial permeability caused by thrombin [176]. 
Some other factors, such as TGF-, C5a-activated neutro-
phils, HIV infected monocytes, CCL2, ICAM-1, Cryptococ-
cus neoformans, histamine and VEGF may also utilize this 
pathway [30,48,130,163,179]. Besides inducing specific ac-
tin filament polymerization (stress fiber formation) which in 
turn generates contractile intraendothelial forces, RhoGT-
Pase family members (Rho, ROCK) also induce phosphory-
lation of TJ and AJ proteins and their redistribution [26]. 
Two possibilities of how Rho and ROCK act are direct ac-
tion on TJ and AJ complexes and indirect action via down-
stream activation of other signaling molecules (e.g. PKC) 
[162]. 
  The signaling pathways involved in regulating BBB per-
meability are still the subject of the very intensive investiga-
tion. Much current investigation is focused on defining the 
role of novel multiple signal pathways associated with BBB 
“opening” and how they interact at multiple levels. This is 
important in determining how signals are integrated and af-
fect the phosphorylation of junction proteins and/or actin 
cytoskeletal remodeling.  
LESSONS FROM BBB PATHOLOGY  
  Disruption of the BBB is generally believed to be harm-
ful in most circumstances as it can cause the influx of leuko-
cytes, potentially neuroactive compounds and water (edema) 
from blood. Many CNS diseases, including a diverse range 
of inflammatory diseases, diabetes, cancer, and microbial 
infection, cause such disruption. More often than not, this 
reflects a change in the TJ itself.  
  The most progressive BBB breakdown is associated with 
a diverse range of CNS inflammatory conditions. Whether 
the inflammation is primary, resulting from infection (men-
ingitis, meningoencepahlits, encephalitis HIV infections) or 
an autoimmune disorder (multiple sclerosis), or secondary 
(as occurs following stroke or brain trauma), BBB break-
down is associated with several changes in brain endothelial 
phenotype (proinflammatory phenotype), junctional complex 
remodeling and a progressive increase in leukocyte infiltra-
tion [2,44,79,82,124,128,131,145,171]. Under some circum-
stances (stroke and brain trauma), vasogenic brain edema 
develops as a result of junction disruption [44,145]. A vari-
ety of inflammatory mediators participate in these pathologi-
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ferent cytokines (IL-1, TNF-, INF-), chemokines (CXCL8, 
CCL2) matrix metalloproteinases (MMP-2, MMP9) and ad-
hesion molecules (ICAM-1) play a role, which may be direct 
or indirect, via attraction of leukocytes [6,43,45,99,105,115, 
127,137,164,190].  
  Neurodegenerative disease like Alzheimer or Parkinson 
disease may also display changes in BBB permeability 
[42,62]. Clinical and experimental studies show that BBB 
impairment is closely associated with increased rates of neu-
rodegeneration in patients with Alzheimer disease and trans-
genic mice overexpressing APP695 in Tg2576 mice [62,87]. 
Increased BBB permeability is indeed hypothesized as a po-
tential mechanism by which vascular -amyloid accumulates 
in the brain parenchyma [23,87]. Transient BBB opening 
occurs in Parkinson’s disease, although most impairment 
occurs at the blood-cerebrospinal fluid barrier [42]. Again, 
such disruption is associated with transient secretion of in-
flammatory mediators. 
  Transient “opening” of BBB is also present before, dur-
ing and after epileptic seizures. There a multiple factors in-
volved in etiology of BBB impartment in epilepsy, including 
inflammatory mediators (epilepsy associated with stroke or 
brain trauma) and metabolic disorders [102]. 
  Either primary or secondary (metastasis in the brain) 
brain tumors can induce BBB disruption. This is associated 
with disturbance of TJ complex which is manifested as a loss 
of staining for claudin-5, occludin and ZO-1. In addition, 
newly formed blood vessels in gliomas have abnormal TJ 
complexes with very low expression of some critical TJ pro-
teins [93,145]. Alterations in BBB permeability are thought 
to be caused by accumulation of growth factors (VEGF or 
HGF) as well as proinflammtory cytokines [145]. One con-
sequence of BBB disruption in brain tumors is the develop-
ment of vasogenic edema which may be fatal. 
  Diabetes types II, hepatic encephalopathy (caused by 
hyperammonemia), or encephalopathy linked to thiamine 
deficiency are some of the metabolic disorders associated 
with BBB disturbance [149,170,183]. Accumulation of oxi-
dative mediators, cytokines or matrix metalloproteinase 
MMP-9 are some of the factors that may be involved in BBB 
disruption in these conditions [72,76].  
  What lessons can be drawn from these neuropathological 
conditions? One common underlying factor for all of these 
neuropathological conditions is that inflammation and in-
flammatory mediators have a critical role in BBB disruption. 
These inflammatory factors mostly act focally/locally to in-
duce paracellular opening (TJ complex remodeling). In-
flammatory mediators and the process of inflammation may, 
therefore, be a good target for controlling BBB “opening” 
and “closing”. 
NEUROPHAMACOLOGICAL SIGNIFICANCE OF 
BBB “OPENING” 
  There are two major reasons why is important to under-
stand the mechanism underlying BBB “opening” and to be 
able to control such disruption. First, uncontrolled BBB 
“opening” may damage the brain parenchyma by enhancing 
leukocyte influx and vasogenic edema (e.g. in stroke, brain 
trauma or multiple sclerosis). Second, the normal BBB re-
stricts the entry of potential therapeutic agents into brain. 
This, in large portion, has limited successful treatment of 
many severe CNS conditions such as brain tumors and neu-
rodegenerative diseases [185]. The ability to modulate BBB 
permeability would enable physicians to prevent the adverse 
effects of BBB disruption in disease states or to enhance 
BBB permeability to permit the efficient transfer of drugs to 
brain.  
  Currently, the only therapeutic agents in use that improve 
BBB integrity are steroids [185]. They can have a marked 
effect on edema formation in tumors but are not effective in 
stroke. The precise mechanisms by which steroids (dex-
amethasone, hydrocortisone) affect the BBB are still uncer-
tain. However, several in vitro and in vivo studies indicate 
that steroid therapy promotes BBB integrity through anti-
inflammatory actions (decreased cytokine production and 
NFB activation) as well as by stabilizing the TJ complex 
[139,184]. Some in vitro studies have indicated that hydro-
cortisone increases occludin mRNA and protein by acting on 
the occludin promoter region via the glucocorticoid receptor 
[139,184].  
  Inflammatory mediators appear to play a role in BBB 
disruption in many disease states and, therefore, inhibition of 
cytokines, chemokines or adhesion molecules is a potential 
therapeutic target [57]. Unfortunately, the use of antibodies 
to target cytokines and adhesion molecules in man has so far 
failed because of unwanted side effects [57]. There have 
been some promising results with chemokine inhibition, due 
to the fact that small peptide chemokine inhibitors display 
much less side effect.  
  Another potential therapeutic strategy is directed at stabi-
lizing brain endothelial cell:cell interactions and the junc-
tional complex. For example, S1p or SSeCKS mediators 
appear to decrease BBB permeability by acting primarily on 
TJ proteins [89,90]. Their activity is still the subject of in-
tense investigation and it will be very interesting to see 
which signal molecules are involved in their actions on TJ 
proteins. 
  Another strategy, which is in the recent years has been 
gaining more attention, is targeting the signals molecules 
involved in remodeling junctional complexes. For example, 
targeting Rho, Rho kinase, MLCK, PTKs or PKC isoforms 
could be a promising strategy. RhoGTPases have significant 
effects on BBB integrity and the inflammatory response. 
They act as “on-and off-switches” and have a fundamental 
importance for increased permeability as well as in the time-
dependent restoration of endothelial barrier function. Selec-
tive RhoGTPase inhibitors have produced promising results 
in some of the vascular as well as cerebrovascular disorders 
[30,182].  
OPENING THE BBB FOR DRUG DELIVERY 
  In conditions such as brain tumors, neurodegenerative 
disorders like Alzheimer’s disease, Parkinson’s disease or 
different types of metabolic disorders with developing en-
cephalopathy, therapeutic strategies are often limited by the 
inability of drugs to cross the BBB from blood to brain. 
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for disrupting the BBB. The ultimate goals of such methods 
are several: (i) there should be specificity in targeting the 
brain or preferably the diseased/injured part of the brain; (ii) 
the action should be brief in duration with the paracellular 
opening reverting back to control quickly; and (iii) the 
paracellular leak should be specific for the class of molecules 
one wishes to deliver.  
  There are several options for transiently disrupting the 
BBB. The most widely studied method involves intra-arterial 
injection of a hyperosmolar osmotic such as mannitol, which 
leads to endothelial cell shrinkage and opening of TJ. This 
method has been used extensively to deliver chemotherapeu-
tic agents to gliomas, neuroectodermal tumors, CNS lym-
phomas, and brain metastases in animal models and patients 
by Neuwelt and colleagues [63,84,152]. Some specificity in 
targeting is achieved by injecting the hyperosmotic agent 
unilaterally into the cerebral circulation. Further data is still 
required before this technique gains widespread use.  
  Bradikinin and its analog RPM-7 (B2 receptor agonist) 
have also been investigated as potential inducers of transient 
BBB disruption [13,135]. Despite its longer half-life and 
greater selectivity, the use of RMP-7 in conjunction with 
chemotherapy showed no benefit in a randomized phase 2 
trials for gliomas.  
  Other potential methods to induce transient “opening” of 
BBB are intra-arterial administration of alkilglycerola, which 
transiently increases the penetration of drugs or macromole-
cules across the BBB, and exposure of BBB to radiotherapy 
(20-30Gy) whilst chemotherapy is administered [47,84,138]. 
These strategies are under intense investigation in order to 
understand their mechanisms of action at the BBB and pos-
sible side effects.  
  A promising target to induce transient opening of the 
BBB for drug delivery may also be the signaling molecules 
involved in regulation of BBB permeability. We would like 
to point out that effect of Rho and Rho kinase in transient 
opening of brain endothelial barrier should be take in consid-
eration for the further investigation of drugs deliver into 
brain. 
  An alternative strategy for drug delivery across the BBB 
focuses on transcytosis and transcellular permeability. En-
hanced vesicular transport can be used for delivery com-
pounds into the brain. Examples are: liposome-born thera-
peutic agents that show more transendothelial passage under 
hypothermic conditions and compounds which bind to lect-
ins and via adsorptive vesicular transport are taken up into 
brain parenchyma [10,11,105,189]. Modulation of specific 
endothelial carrier proteins (transporters) is also a therapeutic 
target for enhancing drug delivery across the BBB. Such 
transporters may be involved in transport of compounds 
from blood to brain, in which case drugs which are substrates 
will have enhanced delivery (e.g. L-DOPA is a substrate for 
the L-system amino acid transporter). There are, however, 
also efflux transporters which clear compounds from the 
brain. P-glycoprotein (P-gp) is the major BBB efflux trans-
porter and mice that lack P-gp have higher brain uptake of a 
wide range of drugs [96,180]. There has, therefore, been a 
major effort by drug companies to develop P-gp inhibitors to 
enhance the delivery of drugs to the brain. As yet, there have 
been no clinical trials that have shown a benefit of this ap-
proach to enhance drug delivery to brain. 
  From clinical and neuropathological point of view, con-
trolling BBB permeability has tremendous importance in 
treatment of the devastating brain disorders. From the neuro-
pharmacological point of view controlling BBB permeability 
should be effective, and without or with limited side effects. 
Thus, understanding BBB structure and the molecular 
mechanisms of regulating BBB permeability opens a new 
avenue of therapeutic strategies for most brain disorders. 
CONCLUSION  
  Much exciting progress is being made in understanding 
the molecular basis of BBB paracellular permeability. Al-
though some details remain obscure, the TJ is likely to be 
site where multiple cellular signaling pathways converge to 
regulate paracellular permeability. Due to this fact, further 
intensive investigation is needed to completely understand 
the mechanism of regulating permeability, but they promise 
to make important findings for the treatment of severe CNS 
diseases such as multiple sclerosis, stroke, infections and 
brain tumors.  
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